＂Ihe management of castrate-resistant prostate cancer progressing after maximum androgen blockade （MAB） has evolved in the last decade with the development of several novel therapeutic options. However, the initial...＂Ihe management of castrate-resistant prostate cancer progressing after maximum androgen blockade （MAB） has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of anti-androgen that can be associated with biochemical response in approximately 20% of patients. Notably; we have observed evidence of sustained biochemical response in two patients following second- and third-line MAB using rechallenge schedule of previously administered anti-androgen after latent interval. The possibility of response following sequential MAB using the same anti-androgen agent has not yet been reported.展开更多
文摘＂Ihe management of castrate-resistant prostate cancer progressing after maximum androgen blockade （MAB） has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of anti-androgen that can be associated with biochemical response in approximately 20% of patients. Notably; we have observed evidence of sustained biochemical response in two patients following second- and third-line MAB using rechallenge schedule of previously administered anti-androgen after latent interval. The possibility of response following sequential MAB using the same anti-androgen agent has not yet been reported.
